๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

โœ Scribed by Lachance, Daniel H. ;Oette, Dagmar ;Schold, S. Clifford ;Brown, Mark ;Kurtzberg, Joanne ;Graham, Michael L. ;Tien, Robert ;Felsberg, Gary ;Colvin, O. Michael ;Moghrabi, Albert ;Browning, Iley ;Hockenberger, Beverly ;Stewart, Elizabeth ;Ferrell, Lee ;Kerby, Tracy ;Duncan-Brown, Margaret ;Golembe, Barry ;Fuchs, Herb ;Fredericks, Ruth ;Hayes, Frances Ann ;Rubin, Abbe Sue ;Bigner, Darell D. ;Friedman, Henry S.

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
634 KB
Volume
24
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The role of systemic high-dose cytarabin
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patients
โœ Enrica Morra; Mario Lazzarino; Ercole Brusamolino; Guido Pagnucco; Carlo Castagn ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 701 KB

Background. Given the good penetration of systemic high-dose cytarabine (HDara-C) into the cerebrospinal fluid (CSF), this approach was used to treat patients with central nervous system (CNS) leukemia, either isolated or with concurrent extraneurologic disease (END). Methods. From 1983 to 1991,46

Central nervous system changes complicat
Central nervous system changes complicating the use of radiotherapy for the treatment of a nasopharyngeal neoplasm in a diabetic patient
โœ Bruce M. Smith; William McGinnis; John Cook; Howard Latourette ๐Ÿ“‚ Article ๐Ÿ“… 1979 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 616 KB

A case is reported of a diabetic patient with a nasopharyngeal neoplasm who developed radiation induced brainstem damage even though irradiated at a conventional time-dose-volume relationship. The clinical course was correlated with autopsy findings which revealed radiation changes in the brainstem

A Phase I dose escalation trial of conti
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma
โœ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB ๐Ÿ‘ 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou